When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about DexCom (DXCM) .DexCom currently has an average brokerage recommendation (ABR) of 1.20, on a sca ...

DexCom (DXCM) ended the recent trading session at $133.04, demonstrating a -1.63% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.11%. Meanwhile, the Dow gained 0.12%, and the Nasdaq, a tech-heavy index, lost 0.41%.Heading into today, shares of the medical device company had gained 12.27% over the past month, outpacing the Medical sector's gain of 3.03% and the S&P 500's gain of 2.7% in that time.The upcoming earnings release of DexCom will be of ...

A good way to invest in the healthcare industry's continued growth is by targeting businesses that make medical devices. Such equipment aids physicians in surgery, helps patients recover, and can assist people in staying on top of chronic conditions, including hypertension and diabetes.This hasn't exactly been a hot place to invest in, however. Since 2021, the iShares US Medical Devices ETF has risen by just 6%, while the S&P 500 has achieved gains in excess of 36%. But as many investors have been overlooki ...

Shares of DexCom (DXCM) have gained almost 10% so far this week compared to its closing last Friday. The strong rally in the company’s share price can be attributed to the recent FDA approval of its first glucose biosensor, Stelo, which will provide glucose insights directly to a user’s smartphone. Moreover, the availability of the sensor over-the-counter to consumers without a prescription is likely to broaden Dexcom’s targeted patient population.Stelo is likely to be available for purchase online without ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. DexCom (DXCM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.DexCom is a member of our Medical group, which includes 1067 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Secto ...

DexCom (DXCM) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this medical device company have returned +5.6% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical - Instruments industry, to which DexCom belongs, has gained 3.2% over this period. Now the key question is: Where could the stock be headed in the near term?While media rel ...

DexCom (DXCM) shares ended the last trading session 9.8% higher at $133.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.5% loss over the past four weeks.The surge in stock price was likely driven by FDA clearance for Stelo glucose biosensor, available over-the-counter to consumers without a prescription. As an alternative for people without insurance coverage for continuous glucose monitoring sensors like G7, ...

Key TakeawaysThe S&P 500 moved 0.5% higher on Wednesday, March 6, 2024, after Federal Reserve Chair Jerome Powell told Congress that rate cuts are still likely for some time this year.Dexcom received FDA approval for an over-the-counter continuous glucose monitor, and its shares soared.Shares of Brown-Forman sank after the beverage maker missed revenue estimates amid declining Jack Daniels sales. Major U.S. equities indexes advanced after Federal Reserve Chair Jerome Powell testified in Congress that the ce ...

DexCom Inc. (DXCM) recently announced the FDA clearance of its Stelo glucose biosensor, available over-the-counter to consumers without a prescription.The company’s latest Continuous Glucose Monitoring (CGM) sensor, G7, is currently available on prescription. As an alternative for people without insurance coverage for CGM, Stelo's approval for non-prescription use would further facilitate this population's access to cutting-edge CGM technology.Price PerformanceFor the past six months, DXCM’s shares have gai ...

The most recent trading session ended with DexCom (DXCM) standing at $122.30, reflecting a +0.46% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily loss of 0.12%. Elsewhere, the Dow lost 0.25%, while the tech-heavy Nasdaq lost 0.41%.Shares of the medical device company have appreciated by 0.64% over the course of the past month, underperforming the Medical sector's gain of 3.58% and the S&P 500's gain of 4.83%.Investors will be eagerly watching for ...